1186130-66-4

Basic information

• Product Name: 5-methoxy-2-(3-phenylisoxazol-5-yl)phenol
• Synonyms: 5-methoxy-2-(3-phenylisoxazol-5-yl)phenol
• CAS NO: 1186130-66-4
• Molecular Weight: 267.284
• Mol File: 1186130-66-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-methoxy-2-(3-phenylisoxazol-5-yl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methoxy-2-(3-phenylisoxazol-5-yl)phenol(1186130-66-4)
• EPA Substance Registry System: 5-methoxy-2-(3-phenylisoxazol-5-yl)phenol(1186130-66-4)

Safety Data

• Hazardous Substances Data: 1186130-66-4(Hazardous Substances Data)

Upstream product

• 52752-67-7 1-(2-hydroxy-4-methoxyphenyl)-3-phenylpropane-1,3-dione 

Downstream Products

• 1186130-80-2 ethyl 4-(5-methoxy-2-(3-phenylisoxazol-5-yl)phenoxy)butanoate 
• 1350176-24-7 4-(5-methoxy-2-(3-phenylisoxazol-5-yl)phenoxy)butanoic acid 
• 1186130-69-7 N-isopropyl-N-(2-(5-methoxy-2-(3-phenylisoxazol-5-yl)phenoxy)ethyl)propan-2-amine 
• 1186130-67-5 2-(5-methoxy-2-(3-phenylisoxazol-5-yl)phenoxy)-N,N-dimethylethanamine 
• 1186130-68-6 diethyl{2-[5-methoxy-2-(3-phenylisoxazol-5-yl)phenoxy]ethyl}amine 
• 1186130-72-2 1-{2-[5-methoxy-2-(3-phenylisoxazol-5-yl)phenoxy]ethyl}piperidine 
• 1186130-71-1 [4-methoxy-2-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-3-phenylisoxazole 
• 1186130-70-0 4-(2-(5-methoxy-2-(3-phenylisoxazol-5-yl)phenoxy)ethyl)morpholine 
• 1186130-79-9 ethyl 2-(5-methoxy-2-(3-phenylisoxazol-5-yl)phenoxy)acetate 
• 1186130-73-3 5-(2-(3-chloropropoxy)-4-methoxyphenyl)-3-phenylisoxazole 
• 1186130-81-3 2-(5-methoxy-2-(3-phenylisoxazol-5-yl)phenoxy)acetic acid 
• 1186130-83-5 5-(4-methoxy-2-((oxiran-2-yl)methoxy)phenyl)-3-phenylisoxazole 

Relevant articles and documents

Design and synthesis of 3,5-diarylisoxazole derivatives as novel class of anti-hyperglycemic and lipid lowering agents

We have designed 1,3-disubstituted-5-membered heteroaromatic ring system as a common core motif from known anti-hyperglycemic agents. Designed compounds were synthesized and screened for in vivo anti-hyperglycemic activity in sucrose loaded model (SLM), sucrose-challenged streptozotocin-induced diabetic rat model (STZ-S) as well as db/db mice model. Some of the synthesized compounds showed promising in vivo anti-hyperglycemic as well as moderate lipid lowering activity. Synthesized Compounds were screened in various in vitro models of type-2 diabeties such as DPP-4, PTP1B and PPARγ to know the mechanism of their anti-hyperglycemic action. None of the synthesized compounds showed DPP-4 inhibitory as well as PPARγ activity. These compounds have shown promising PTP-1B inhibitory activity there by revealing that compounds exhibit anti-diabetic activity by PTP1B pathway.